# Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

> **NCT06331169** · PHASE1 · RECRUITING · sponsor: **Fudan University** · enrollment: 42 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT06331169
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331169, "Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06331169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*